Abstract

The mid-regional fragment of the peptide complex Pro-adrenomedullin (MR-proADM) is a ubiquitous biomarker tissue distribution in the human body with increased levels in the course of certain diseases of great importance for vital engagement and whose clinical course is often associated with dyspnoea. Prospective observational analytical survey conducted on a group of 191 selected patients requiring urgent treatment with NIV due to acute or exacerbated chronic dyspnoea from any cause, except surgical or neuromuscular, between November 2012 and December 2013, to which they were, extracted a blood sample at the time of initiation of therapy with NIV to determine the MR-proADM. The first aim of our study was to establish the association between plasma levels of MR-proADM and in-hospital mortality in patients undergoing NIV for acute respiratory failure regardless of source. The median age of patients was 79-years-old and overall mortality by 22%. Mid-regional pro-adrenomedullin presented a median of 0.57 nmol/L (from 0.29 to 3.19 nmol/L), and the same amount was obtained for both survivors to deceased. In our survey, the MR-proADM has not shown the ability to forecast for 30-day mortality of patients requiring treatment with NIV for acute respiratory failure, regardless of the precipitating pathology.

Authors and Affiliations